Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC (AZN) generates a steady flow of news driven by its global biopharmaceutical activities in Oncology, Rare Diseases and BioPharmaceuticals. Company announcements frequently cover clinical trial milestones, regulatory decisions, manufacturing investments and strategic collaborations, offering investors and healthcare professionals insight into how its pipeline and marketed medicines are evolving.
Recent news highlights include multiple updates on Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), two antibody drug conjugates jointly developed with Daiichi Sankyo. These stories describe new Phase 3 trials, Breakthrough Therapy Designations, and approvals in indications such as HER2-positive early breast cancer, metastatic breast cancer, HER2-expressing endometrial cancer and HER2-expressing ovarian cancer, as well as TROP2-directed approaches in lung and breast cancer.
News items also cover immuno-oncology developments with Imfinzi (durvalumab), including perioperative regimens for gastric and gastroesophageal junction cancers based on the MATTERHORN trial, and broader use in gastrointestinal and thoracic malignancies. In Rare Diseases and immunology, AstraZeneca reports on approvals for Koselugo in adult NF1-associated plexiform neurofibromas and on expanded administration options for Saphnelo in systemic lupus erythematosus.
Beyond clinical and regulatory updates, AstraZeneca’s news feed includes information on large-scale manufacturing investments in the United States, such as expansion of biologics facilities in Maryland, and technology partnerships like the selection of Salesforce’s Agentforce Life Sciences platform for AI-powered customer engagement. Visitors to this AZN news page can review these developments to understand how AstraZeneca’s pipeline, approvals and infrastructure may influence its long-term strategic direction.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced the FDA has accepted the sBLA for DATROWAY (datopotamab deruxtecan-dlnk) and granted Priority Review for 1st-line treatment of unresectable or metastatic triple-negative breast cancer (TNBC) in patients ineligible for PD-1/PD-L1 inhibitors. The FDA action date is anticipated in Q2 2026 under Project Orbis.
Results from TROPION-Breast02 showed a median overall survival improvement of 5.0 months (HR 0.79; 95% CI 0.64-0.98; p=0.0291), a 43% reduction in risk of progression or death (HR 0.57; 95% CI 0.47-0.69; p<0.0001), ORR 62.5% and DoR 12.3 months versus chemotherapy.
AstraZeneca (AZN) and Daiichi Sankyo announced the sBLA for DATROWAY was accepted and granted Priority Review in the U.S. for first-line unresectable/metastatic triple negative breast cancer patients not eligible for immunotherapy.
The submission, reviewed under Project Orbis, is supported by TROPION-Breast02 results: median overall survival improved by 5.0 months (HR=0.79; p=0.0291), progression risk reduced by 43% (HR=0.57; p<0.0001), ORR 62.5% and DoR 12.3 months. PDUFA date: June 2, 2026.
AstraZeneca (NYSE/LSE/STO: AZN) began trading ordinary shares on the New York Stock Exchange on 2 February 2026, creating a harmonized global listing across New York, London and Stockholm. The company says this expands US investor access while maintaining LSE and STO listings and index inclusion.
AstraZeneca noted a >$10bn peak revenue opportunity from recent pipeline readouts and reiterated a 2030 ambition of $80bn annual revenue and launching 20 new medicines.
AstraZeneca (AZN) and Daiichi Sankyo announced that on January 19, 2026 the European Medicines Agency validated a Type II Variation application to expand marketing authorization for ENHERTU (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2 positive breast cancer. The validation starts the CHMP scientific review. The application is supported by the DESTINY-Breast09 phase 3 trial, which showed a statistically significant improvement in progression-free survival versus THP and was presented at ASCO 2025 and published in The New England Journal of Medicine. The companies noted a recent U.S. approval for this indication and said they will work with the EMA during review.
AstraZeneca (AZN) and Daiichi Sankyo initiated TROPION-Lung17, a phase 3 trial testing DATROWAY (datopotamab deruxtecan) versus docetaxel in patients with previously treated, locally advanced or metastatic nonsquamous NSCLC that are TROP2 NMR positive. The trial prospectively enrolls patients using AstraZeneca’s Quantitative Continuous Scoring (QCS) TROP2 NMR biomarker; the investigational AI-powered companion diagnostic has received a Breakthrough Device Designation in the U.S. The first patient has been dosed, and TROPION-Lung17 is the ninth phase 3 study of DATROWAY in NSCLC.
AstraZeneca (NYSE:AZN) appointed Rick R. Suarez as Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit, effective immediately and based in Wilmington, Delaware. Suarez will lead execution of the company’s $50 billion US R&D and manufacturing investment, which includes a $4.5 billion manufacturing facility in Virginia — AstraZeneca’s largest single manufacturing investment. The investment supports a target of $80 billion total revenue by 2030, with roughly half expected from the US. Suarez returns from serving as Country President for Spain and brings more than 20 years of US healthcare experience across commercial, medical and market access roles.
AstraZeneca (NYSE:AZN) announced that ENHERTU (fam-trastuzumab deruxtecan-nxki) received Breakthrough Therapy Designation (BTD) in the US on December 22, 2025 for adult patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment and high risk of recurrence.
The FDA decision was based on positive DESTINY-Breast05 Phase III results presented at ESMO 2025 and published in The New England Journal of Medicine. This marks ENHERTU's tenth BTD and targets the post-neoadjuvant setting to reduce invasive disease recurrence.
AstraZeneca (AZN) and collaborators have dosed the first patient in the DESTINY-Endometrial02 phase 3 trial testing ENHERTU® (trastuzumab deruxtecan) as adjuvant therapy versus standard chemotherapy, with or without radiotherapy, for patients with HER2 expressing (IHC 3+/2+) endometrial cancer.
The global trial is conducted with The GOG Foundation and ENGOT (lead group GINECO). ENHERTU is co‑developed with Daiichi Sankyo. The release notes HER2 expression in ~18%–56% of endometrial cancers and a 39%–56% 18‑month recurrence/death rate in high‑risk patients after standard adjuvant care. There are currently no approved HER2 directed adjuvant therapies for this indication.
ENHERTU (AstraZeneca: AZN) received U.S. Breakthrough Therapy Designation on December 22, 2025, for adult patients with HER2 positive early breast cancer with residual invasive disease after neoadjuvant therapy and high recurrence risk.
The FDA granted BTD based on the DESTINY-Breast05 phase 3 results presented at ESMO 2025 and published in The New England Journal of Medicine, which showed ENHERTU may reduce invasive disease recurrence versus the current standard of care. This is ENHERTU's tenth BTD and the sixteenth BTD across Daiichi Sankyo's oncology portfolio.
AstraZeneca (AZN) and Daiichi Sankyo announced the European Medicines Agency has validated a Type II Variation application for DATROWAY (datopotamab deruxtecan) as first-line monotherapy for adults with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors.
The application, based on the pivotal TROPION-Breast02 phase 3 trial presented at ESMO 2025, showed statistically significant improvements in overall survival (OS) and progression-free survival (PFS) versus investigator's choice chemotherapy. Validation starts the EMA scientific review; additional global submissions are underway.